Lange, Christian M; Bibert, Stephanie; Kutalik, Zoltan; Burgisser, Philippe; Cerny, Andreas; Dufour, Jean-François; Geier, Andreas; Gerlach, Tilman J; Heim, Markus H; Malinverni, Raffaele; Negro, Francesco; Regenass, Stephan; Badenhoop, Klaus; Bojunga, Jörg; Sarrazin, Christoph; Zeuzem, Stefan; Müller, Tobias; Berg, Thomas; Bochud, Pierre-Yves; Moradpour, Darius; ... (2012). A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS ONE, 7(7), e40159. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0040159
|
Text
fetchObject.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (156kB) | Preview |
Background
To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Methodology/Principal Findings
Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D3 (25[OH]D3) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061–2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D3<20 ng/mL) during all seasons, but 25(OH)D3 serum levels were not associated with treatment outcome.
Conclusions/Significance
Our study suggests a role of bioactive vitamin D (1,25[OH]2D3, calcitriol) in the response to treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D3 is not a suitable predictor of treatment outcome.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie |
UniBE Contributor: |
Dufour, Jean-François |
ISSN: |
1932-6203 |
Publisher: |
Public Library of Science |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:38 |
Last Modified: |
05 Dec 2022 14:11 |
Publisher DOI: |
10.1371/journal.pone.0040159 |
PubMed ID: |
22808108 |
Web of Science ID: |
000306366400015 |
BORIS DOI: |
10.7892/boris.15205 |
URI: |
https://boris.unibe.ch/id/eprint/15205 (FactScience: 222497) |
Actions (login required)
 |
Edit item |